Zobrazeno 1 - 4
of 4
pro vyhledávání: '"F. A. Amossenko"'
Autor:
M. A. Emelyanova, F. A. Amossenko, A. V. Semyanikhina, V. A. Aliev, Yu. A. Barsukov, L. N. Lyubchenko, T. V. Nasedkina
Publikováno v:
Molecular Biology. 49:550-559
Autor:
F. A. Amossenko, Lyudmila Lyubchenko, V. A. Aliev, Yu. A. Barsukov, T. V. Nasedkina, A. V. Semyanikhina, M. A. Emelyanova
Publikováno v:
Молекулярная биология. 49:617-627
Somatic mutations of KRAS, PIK3CA, and BRAF cause insensitivity of colorectal tumors to therapy with anti-EGFR monoclonal antibodies, necessitating a genetic testing prior to therapy. A biological microchip was developed and validated to allow detect
Autor:
F. A. Amossenko, Tatiana P. Kazubskaya, T. V. Nasedkina, Sergey Surzhikov, L. N. Lubchenko, M. A. Emelyanova, Alexander V. Chudinov
Publikováno v:
Scopus-Elsevier
Somatic mutations in the KRAS gene are important markers of some types of tumors, for example, pancreatic cancer, and may be useful in early diagnostics. A biochip has been developed which allows deter-mining most frequent mutations in 12, 13, and 61
Autor:
M A, Emelyanova, F A, Amossenko, A V, Semyanikhina, V A, Aliev, Yu A, Barsukov, L N, Lyubchenko, T V, Nasedkina
Publikováno v:
Molekuliarnaia biologiia. 49(4)
Somatic mutations of KRAS, PIK3CA, and BRAF cause insensitivity of colorectal tumors to therapy with anti-EGFR monoclonal antibodies, necessitating a genetic testing prior to therapy. A biological microchip was developed and validated to allow detect